ALLEGRO-LT: Long-Term Safety and Efficacy of Ritlecitinib in Alopecia Areata

Phase 3, open-label trial of ritlecitinib tosilate in alopecia areata (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Serious Adverse Events and Adverse Events Leading to Discontinuation and 3 more. Started Jul 2019; status: completed.